Subcutaneous Fat
Conditions
Brief summary
The purpose of this study is to compare non invasive treatments using a YAG and Didode Laser to reduce the volume of fat.
Interventions
DEVICEDiode Laser
Diode Laser for treatment of subcutaneous fat
DEVICEYAG laser
YAG laser for treatment of subcutaneous fat
Sponsors
Cynosure, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* A healthy non-smoking male or female between 20-60 years of age * Subjects presenting excess abdominal tissue (fat and skin), are candidates for an abdominoplasty procedure and are willing to allow the use of this device on their skin * Subjects who will allow the excess skin removed as part of the abdominoplasty to be sent for laboratory analysis * Understand and accept the obligation associated with the procedure * Subjects with Fitzpatrick skin types I to III. * Subjects who are willing to consent to participate in the study will be asked to undergo biopsies, ultrasound measurements, and blood testing as outlined for each group and defined in section 6.0. * Subjects must agree to maintain the same diet and exercise regime throughout the study
Exclusion criteria
* Any previous liposuction/lipo-sculpture or any type of procedure in the abdominal area in the past 6 months * A history of allergic reactions to medications or anesthesia required for the procedure * A history of thrombophlebitis * A history of acute infections * A history of heart failure * Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E or anti-inflammatories within 2 weeks pre treatment * Intolerance to anesthesia or medications to be prescribed before or after the procedure. * Any medical condition, that, in the investigator's opinion would interfere with the patient's participation in the study including EMLA cream or percocet * Taking medications that are photosensitive * A history of keloid formation * A study subject must not be pregnant or have been pregnant in the last 3 months * The physician has the right to make determination of eligibility as he/she deems clinically significant based on standard of care treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biopsy of Tissue Samples as a Measure of Effectiveness | 5 months post treatment | Biopsy of treated area will be obtained up to 5 months post treatment and will be histologically assessed for changes in adipocytes and surrounding tissue to determine effectiveness of device. |
| Ultrasound Measurement to Evaluate Reduction of Fat | 5 months post treatment | Ultrasound of the treatment area will be performed and evaluated in comparison to baseline results to determine reduction of the subcutaneous fat layer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lipid level blood testing to evaluate changes post treatment | 5 months post treatment | Blood testing will be performed to evaluate changes in lipid levels post treatment |
Countries
United States
Outcome results
None listed